rhuMAb-E25

rhuMAb-E25

Monoclonal anti–IgE antibody, Omalizumab Immunology A recombinant humanized monoclonal antibody that complexes with free IgE and blocks IgE interaction with mast cells and basophils; rhuMAb-E25 may be used to manage Pts with severe allergic asthma
Mentioned in ?
References in periodicals archive ?
RhuMAb-E25, an anti-IgE monoclonal antibody in development by Genentech/Hoffmann-La Roche and Tanox Biosystems/Novartis, is the novel therapeutic most advanced in development.
Tanox is independently evaluating Hu-901 for the treatment of IgE-mediated allergic diseases outside the current clinical focus of rhuMab-E25 anti-IgE, which is being jointly developed in collaboration with Genentech and Novartis.
NYSE:GNE) announced today positive preliminary results from a Phase II trial in which the efficacy of rhuMAb-E25, a recombinant humanized monoclonal antibody to IgE called E25, was tested in adults and adolescents with moderate to severe asthma.